Chronic Myeloid Leukemia

December 7-10, 2013; New Orleans, Louisiana
In this Expert Analysis, Jorge E. Cortes, MD, and Michael J. Mauro, MD, provide an in-depth review of the most clinically relevant new data presented at the 2013 American Society of Hematology meeting on current and emerging therapies for the treatment of chronic myeloid leukemia.
Jorge E. Cortes, MD
Michael J. Mauro, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: February 21, 2014 Expiration: February 20, 2015

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply new data on therapeutic approaches with potential importance in the treatment of patients with chronic myeloid leukemia
  • Use recent data on prognostic factors to improve the clinical management of patients with chronic myeloid leukemia
  • Discuss with patients clinical trials of novel approaches for chronic myeloid leukemia for which they may be eligible

Acknowledgements

Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
Celgene Corporation
Genentech BioOncology
Gilead Sciences
Takeda Oncology
Novartis Oncology
Seattle Genetics

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Jorge E. Cortes, MD

Professor of Medicine, Deputy Chair
Department of Leukemia
The University of Texas MD Anderson Cancer Center 
Houston, Texas

Jorge E. Cortes, MD, has disclosed that he has received funds for research support from Ariad, Bristol-Myers Squibb, ChemGenex, Novartis, and Pfizer and consulting fees from Ariad, Bristol-Myers Squibb, Pfizer, and Teva.
Michael J. Mauro, MD

Leader, Myeloproliferative Diseases Program
Member and Attending Physician, Leukemia Program
Memorial Sloan-Kettering Cancer Center
New York, New York

Michael J. Mauro, MD, has disclosed that he has received consulting fees from Ariad, Bristol-Myers Squibb, Pfizer, and Novartis.

Staff

Andrew D. Bowser, ELS, CCMEP

Editorial Director, Hematology/Oncology

Andrew D. Bowser, ELS, CCMEP, has no significant financial relationships to disclose.
Edward King, MA

Chief Innovation Officer

Edward King, MA, has no significant financial relationships to disclose.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no significant financial relationships to disclose.
Timothy A. Quill, PhD

Managing Editor

Timothy A. Quill has no significant financial relationships to disclose.
Jill Sakai, PhD

Editorial Contributor

Jill Sakai has no significant financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Schultz, RN, MSN, CCMEP and Eric D. Peterson, EdM, FACEHP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hematologists/oncologists and other healthcare professionals who provide care for patients with hematologic malignancies and disorders.

Goal

The goal of this activity is to enable participants to apply the latest insights and clinical advances for the optimal management of patients with hematologic malignancies and disorders.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 21, 2014, through February 20, 2015:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

From Clinical Care Options (CCO), video featuring expert insights on best practices for nurses within a multidisciplinary CAR T-cell therapy care team

person default Caron A. Jacobson, MD
Program Director
Alix Beaupierre, BSN, RN, OCN person default Kathleen McDermott, RN, BSN, OCN, BMTCN
Registered Nurses: 2.0 Nursing contact hours Released: July 8, 2020 Expired: July 7, 2021

Downloadable slides with expert analysis of second-line treatment of CML with TKIs after progression, from Clinical Care Options.

Jorge Cortes, MD Released: July 8, 2020

Gain key clinical insights fast, with this short slideset from CCO on treatment options for patients with myeloma

Sarah A. Holstein, MD, PhD person default David M. Kaufman, MD Released: July 7, 2020

Living slideset on optimal management of CLL during the COVID-19 pandemic will be continually up-to-date as the situation evolves and new data emerge

Jacqueline Barrientos, MD, MS Nicole Lamanna, MD John Pagel Headshot John Pagel, MD, PhD person default Jacob D. Soumerai, MD Released: July 2, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?